On the other hand, the median survival of JAK2-nonmutated CMML patients, which was also in the range of other published CMML cohorts, was not different from MPN patients with a CMML-like phenotype suggesting that with regard to prognosis this group was more similar to CMML than to PV. This evidence concerns the gene JAK2 and myeloproliferative disorder.